Lenalidomide vs methotrexate for hard-to-treat lupus skin disease
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial compares two drugs, lenalidomide and methotrexate, to see which works better for people with active cutaneous lupus (skin lupus) that hasn't improved with standard treatments. You would be randomly assigned to one of the two drugs and followed for several months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have a confirmed diagnosis of active cutaneous lupus (skin lupus), with or without systemic lupus.
- Your skin lupus must have a certain level of activity (a score of at least 8 on a standard skin activity scale).
- You have tried antimalarial drugs (like hydroxychloroquine) for at least 3 months or had to stop them due to side effects.
- You are willing to use effective birth control and have monthly pregnancy tests if you could become pregnant.
- You do not have severe lupus affecting organs like kidneys or brain, active cancer, or a history of blood clots in the last 5 years (unless you have antiphospholipid syndrome on warfarin).
- You have not taken certain other immune-suppressing drugs or biologics for lupus in the past 4–12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if quinacrine, an oral drug, improves skin rashes caused by lupus. You may be eligible if you have a type of skin lupus called SCLE or DLE that hasn't improved with standard treatments like steroids or hydroxychloroquine.
This study tests a new injectable drug, HC022, for people with lupus or cutaneous lupus. It aims to see if the drug is safe, tolerable, and begins to work.
This trial tests an experimental drug called ICP-488 for people with active cutaneous lupus erythematosus (CLE), a type of lupus that affects the skin. It aims to see if the drug can reduce skin inflammation and improve symptoms.
This trial tests two new drugs, BCD-256-1 and divozilimab, for people with systemic lupus erythematosus (SLE) who have active skin symptoms not controlled by current treatments. The goal is to see if they are safe and how the body processes them.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This trial tests a new treatment called CM355 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. It aims to see if the drug can help control disease activity in patients whose lupus is not well managed by current therapies.
Hear when a new Cutaneous Lupus Erythematosus (CLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.